Aclarion, Inc. (ACON) Stock Price & Analysis
Aclarion, Inc. (ACON) fell 1.22% to USD 2.42 as of July 25, 2026 at 02:22 UTC, according to Nexqual real-time market data.
ACON last closed at USD 2.45; the session ranged USD 2.4–2.51 on volume of 22,023 shares. Market capitalization is $5.96M, with a 52-week range of USD 2.34–12.03 (NCM). Source: Nexqual, July 25, 2026 at 02:22 UTC.
Key Statistics (as of July 25, 2026 at 02:22 UTC)
| Price | USD 2.42 |
|---|---|
| Change | ▼ 1.22% (down) |
| Previous Close | USD 2.45 |
| Open | USD 2.46 |
| Day Range | USD 2.4 – 2.51 |
| 52-Week Range | USD 2.34 – 12.03 |
| Volume | 22,023 shares |
| Market Cap | $5.96M |
| Exchange | NCM |
Technical Analysis (ACON)
Nexqual's technical model rates ACON "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.78 (oversold) |
| vs SMA50 | Below (USD 3.02) |
| MACD | -0.16 (negative) |
Analyst Ratings (ACON)
Wall Street analysts rate ACON "None" based on 1 analysts, with a mean price target of USD 7.5 (range USD 7.5–7.5), per Nexqual as of July 25, 2026 at 02:22 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 7.5 |
| High Target | USD 7.5 |
| Low Target | USD 7.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ACON)
| EPS Estimate | USD -1.05 |
|---|---|
| Revenue Estimate | $30,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.34 vs est -1.55 ▲ beat |
| 2025-12-31 | USD -4.52 vs est -3.6 ▼ miss |
| 2025-09-30 | USD -2.93 vs est -2.64 ▼ miss |
| 2025-06-30 | USD -2.75 vs est -2.26 ▼ miss |
Source: Nexqual, July 25, 2026 at 02:22 UTC.
Financials & Fundamentals (ACON)
| Total Revenue | $77,879 |
|---|---|
| Revenue Growth (YoY) | +11.30% |
| Gross Margin | +19.34% |
| Operating Margin | -14129.33% |
| Profit Margin | +0.00% |
| ROE | -45.43% |
| Current Ratio | 19.65 |
| Total Cash | $19.01M |
| Total Debt | $0 |
| Free Cash Flow | $-4.90M |
Source: Nexqual, July 25, 2026 at 02:22 UTC.
Financial Health Score (ACON)
Nexqual rates Aclarion, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 02:22 UTC.
| Growth | Strong — Revenue +66% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $19M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -45%, ROA -28.8% |
Ownership (ACON)
| Insider Ownership | +26.20% |
|---|---|
| Institutional Ownership | +4.35% |
| Shares Outstanding | 2.46M |
| Float | 2.20M |
| Short % of Float | +2.22% |
Source: Nexqual, July 25, 2026 at 02:22 UTC.
Leadership (ACON)
Aclarion, Inc. is led by Brent Ness (age 58), CEO, President & Director, per Nexqual as of July 25, 2026 at 02:22 UTC.
| CEO, President & Director | Brent Ness (age 58) |
|---|---|
| Executive Chairman | Jeffrey John Thramann (age 60) |
| Chief Financial Officer | Gregory A. Gould (age 59) |
| Chief Strategy Officer | Ryan Bond (age 53) |
Major Backers & Investors (ACON)
Notable institutional backers of Aclarion, Inc. include Osaic Holdings Inc., Fidelity, CAPTRUST Financial Advisors, according to Nexqual as of July 25, 2026 at 02:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Osaic Holdings Inc. | 1.42% |
| Fidelity | 0.91% |
| CAPTRUST Financial Advisors | 0.59% |
| Bank of Montreal /CAN/ | 0.41% |
| UBS Group AG | 0.39% |
| Dauntless Investment Group, LLC | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.27% |
| Vanguard Group | 0.56% |
Source: Nexqual, July 25, 2026 at 02:22 UTC.
From Aclarion, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Aclarion, Inc. operates as a healthcare technology company in the United States.
- It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
- The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
- It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| FRGT | Freight Technologies, Inc. | USD 3.01 | ▼ 15.45% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
| SKYA | SkyAI, Inc. | USD 1.39 | ▲ 0% |
| TGL | Treasure Global Inc. | USD 3.06 | ▼ 6.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:22 UTC. This page is informational and not investment advice.